Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

THERMO FISHER SCIENTIFIC

(TMO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

UK Regulator Won't Refer Thermo Fisher's Acquisition of PPD for Further Review

12/03/2021 | 02:32am EST

By Jaime Llinares Taboada

The U.K. Competition and Markets Authority said Friday that it has decided it won't refer Thermo Fisher Scientific Inc.'s planned $17.4 billion acquisition of pharmaceutical-testing company PPD Inc. to a phase 2 investigation.

The regulator had announced a probe into the deal in October, to see if it would lead to a lessening of competition.

Write to Jaime Llinares Taboada at jaime.llinares@wsj.com; @JaimeLlinaresT

(END) Dow Jones Newswires

12-03-21 0232ET

Stocks mentioned in the article
ChangeLast1st jan.
PPD, INC. -0.06% 47.28 End-of-day quote.38.16%
THERMO FISHER SCIENTIFIC 0.28% 595.06 Delayed Quote.-11.56%
All news about THERMO FISHER SCIENTIFIC
01/19Oncocyte Shares Drop 11% After Marketing Deal With Thermo Fisher
DJ
01/18OncoCyte Strikes Deal with Thermo Fisher to Expand Access to Precision Oncology
MT
01/18Oncocyte Announces Development and Co-Marketing Agreement with Thermo Fisher Scientific..
CI
01/11Thermo fisher scientific exec says pricing is going to be higher in 2022 than in past y..
RE
01/11Thermo Fisher Scientific Exec Says Pricing Is Going To Be Higher In 2022 Than In Past Y..
RE
01/11Thermo fisher scientific exec says demand for vaccines will be relevant at least into 2..
RE
01/10SomaLogic Hires Adam Taich as Chief Business Officer
MT
01/07THERMO FISHER SCIENTIFIC INC. : Entry into a Material Definitive Agreement, Termination of..
AQ
01/07Thermo Fisher Scientific Inc. Enters into $5.0 Billion Unsecured Five-Year Revolving Cr..
CI
01/05Thermo Fisher Scientific Completes Acquisition of PeproTech, a Leader in Recombinant Pr..
PR
More news
Analyst Recommendations on THERMO FISHER SCIENTIFIC
More recommendations
Financials (USD)
Sales 2021 37 627 M - -
Net income 2021 7 855 M - -
Net Debt 2021 25 663 M - -
P/E ratio 2021 30,2x
Yield 2021 0,17%
Capitalization 234 B 234 B -
EV / Sales 2021 6,90x
EV / Sales 2022 6,22x
Nbr of Employees 80 000
Free-Float 89,6%
Chart THERMO FISHER SCIENTIFIC
Duration : Period :
Thermo Fisher Scientific Technical Analysis Chart | TMO | US8835561023 | MarketScreener
Technical analysis trends THERMO FISHER SCIENTIFIC
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 22
Last Close Price 593,37 $
Average target price 683,11 $
Spread / Average Target 15,1%
EPS Revisions
Managers and Directors
Marc N. Casper Chairman, President & Chief Executive Officer
Stephen Williamson Chief Financial Officer & Senior Vice President
Ryan Snyder Chief Information Officer & Senior Vice President
Alan B. Sachs Chief Medical Officer
Karen E. Nelson Chief Scientific Officer
Sector and Competitors